Respiratory virus attachment to mucosa

Respiratory virus attachment to mucosa" refers to the initial step in the infection process where respiratory viruses (such as influenza virus, respiratory syncytial virus, or SARS-CoV-2) interact with components of the mucosal barrier in the respiratory tract. These mucosal layers are composed primarily of mucins and glycoconjugates that act as physical and biochemical barriers against infection[1][2][3][6]. Viruses typically attach via specific interactions between viral envelope proteins (such as hemagglutinin for influenza or spike protein for coronaviruses) and host cell surface receptors or glycans (commonly sialic acid-containing glycans or proteins like ACE2)[1][4][6]. Therapeutic agents that inhibit viral attachment often target these interactions broadly (e.g., sialic acid mimetics, glycan-binding inhibitors) rather than a single receptor or molecule[5]. Therefore, "respiratory virus attachment to mucosa" is a key biological process but not a defined molecular target suitable for structured therapeutic targeting.

Inhibition of specific interactions between viral envelope proteins and host cell surface receptors/glycans, thereby preventing viral attachment to the respiratory mucosa.